Pharmacy chains activity analysis

Pharmacy chains activity analysis

Russian pharmaceuticals retail chain segment evaluation, both on the level of the state and in particular regions. Pharmacy chains development forecast

Forecasting

Product sales and separate market development forecast, based on unique mathematical models

Business and marketing plan development

Development of detailed business-plans, required to evaluate the reasonability of project start

Search of partners for contract production in Russia

Potential partners search and evaluation, based on their technical opportunities, appropriate experience, and reputation

Monitoring of import substitution

assessment of the main trends of import substitution policies and localization processes in the pharmaceutical market in Russia, the key beneficiaries and companies at risk

Database Update: Pharmaceutical Drug Import to Russia (October 2018)

Wednesday, December 19, 2018

Between January and October 2018, Russia imported 427.1 bln RUB worth of ready-made pharmaceutical drugs (free circulation prices), which is in monetary terms 1.5% higher than that of the same period of 2017, and 87.9 bln RUB worth of in-bulk pharmaceuticals, which is in monetary terms 12.5% higher than that of the same period of 2017. In total, the dynamics in monetary terms are +3.2%.

In physical terms, Russia imported 1.5 bln units of ready-made pharmaceuticals, or 27.9 bln minimum dosage units (MDU.) The dynamics are -7.6% and -5.8%, respectively. The dynamics of the in-bulk import are +0.8% (3.5 bln MDU. The total import amounts to 31.5 bln units, with the dynamics being -5.1%.

In October 2018, Russia imported 50.1 bln RUB worth of ready-made pharmaceuticals, which is in monetary terms 4.4% higher than that of October 2017, and 6.7 bln RUB worth of in-bulk drugs, which is in monetary terms 16.2% lower than that of October 2017.

Among the top 20 companies with the biggest ready-made pharmaceutical drug import in monetary terms, MSD and Takeda have the highest dynamics. The dynamics of MSD are nearly +28%, with the import of follicle stimulating Purigon having increased by 89 times. The dynamics of Takeda are +25%. Its Alunbrig, used for lung cancer treatment, has not yet been registered in Russia and is imported only for certain patients for health reasons.

As for in-bulk importers, Merck Group and Concor have the biggest dynamics in monetary terms, with a 4.1 and 29 times increase, respectively. Amgen has also good dynamics (+300%), the import of its Vectibix, packaged by Russian Dobrolek, has increased by 5.6 times.

Read more about pharmaceutical drug import to Russia (September results) here: http://rncph.com/news/13_11_2018

Dynamics of import of pharmaceuticals, including homeopathic and seawater drugs, to Russia, free circulation prices including customs clearance and VAT, RUB (January 2017 – October 2018)

Share: